Establishment of an etoposide (VP-16)-resistant subline of THP-1 human monocytic leukemia cell line.
Yasuo Saijo(Ho Chi Minh City International University), Masakichi Motomiya(Tohoku University), Nobuko Kumano(Tohoku University), Sadahiro Koinumaru, Shunichi Sugawara(Sendai Kousei Hospital), Kōtaro Ōizumi(Tohoku University), Shuji Suzuki(Tokyo Institute of Technology)
Cited by 5
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695